| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CXCL13 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CXCL13抗体的参考文献，按文献名称、作者及摘要内容分类整理：
---
**1. 文献名称**: *CXCL13 as a Biomarker of Immune Activation in Chronic Lymphocytic Leukemia*
**作者**: Smith J, et al.
**摘要**: 本研究验证了抗CXCL13抗体在慢性淋巴细胞白血病(CLL)患者血清检测中的应用，发现CXCL13水平与肿瘤微环境中B细胞招募相关，提示其作为疾病进展的生物标志物潜力。
---
**2. 文献名称**: *Targeting CXCL13 in Autoimmune Neuroinflammation*
**作者**: Zhang L, et al.
**摘要**: 通过抗CXCL13抗体的中和实验，作者证明抑制CXCL13可减少多发性硬化小鼠模型中B细胞向中枢神经系统的迁移，为自身免疫性神经炎症提供了潜在治疗靶点。
---
**3. 文献名称**: *CXCL13 Antibody-Based Detection in Follicular Lymphoma Diagnosis*
**作者**: Gupta R, et al.
**摘要**: 该研究开发了一种高特异性抗CXCL13单克隆抗体，用于滤泡性淋巴瘤的免疫组化检测，证实CXCL13高表达与肿瘤相关三级淋巴结构的形成密切相关。
---
**备注**：以上文献为示例，实际引用时需根据具体研究领域补充真实文献信息(可通过PubMed/Google Scholar检索关键词"CXCL13 antibody"+"应用方向"获取)。
CXCL13. a member of the CXC chemokine family, is a key chemoattractant for B-lymphocytes and follicular helper T cells, primarily through its interaction with the CXCR5 receptor. It plays a critical role in lymphoid organogenesis, germinal center formation, and immune responses. Dysregulation of CXCL13 has been implicated in autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), chronic inflammation, and cancers, particularly B-cell lymphomas and tumor microenvironments promoting immune evasion.
CXCL13 antibodies are essential tools for studying its expression, function, and therapeutic targeting. Monoclonal and polyclonal antibodies are widely used in immunohistochemistry, ELISA, and flow cytometry to detect CXCL13 in tissues, serum, or cerebrospinal fluid. In neuroinflammatory disorders like Lyme neuroborreliosis, CXCL13 antibodies aid in diagnosing intrathecal production of the chemokine. Therapeutically, neutralizing antibodies are being explored to inhibit CXCL13-CXCR5 signaling in autoimmune conditions or cancer, potentially disrupting pathogenic lymphocyte recruitment.
Research also highlights CXCL13 as a biomarker for disease progression and treatment response, particularly in checkpoint inhibitor therapies. However, challenges remain in optimizing antibody specificity and delivery for clinical applications. Overall, CXCL13 antibodies bridge basic research and translational medicine, offering insights into immune regulation and novel therapeutic strategies.
×
